'Polypill' for heart failure cuts hospitalizations and ER visits by 60% in trial

by UT Southwestern Medical Center

edited by Gaby Clark, reviewed by Robert Egan

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

A "polypill" combining three medications recommended to treat heart failure into a single daily dose proved far more effective for patients than taking the drugs separately, a randomized clinical trial led by UT Southwestern Medical Center researchers showed. The findings, published in Nature Medicine, could lead to new ways to treat patients with conditions that require taking multiple daily medications to achieve optimal outcomes.

"Despite the existence of medical therapies for heart failure that significantly reduce hospitalization and mortality, use of these treatments remains low," said study lead author Ambarish Pandey, M.D., associate professor of internal medicine in the Division of Cardiology at UT Southwestern.

"Our findings in the POLY-HF trial established that a polypill strategy offers a realistic path to helping patients achieve and maintain optimal therapy for heart failure, a setting where single-pill approaches had not previously been tested."

Heart failure, a chronic condition in which the heart is unable to pump enough blood to meet the body's needs, affects more than 6 million Americans. The prognosis is poor, with nearly half of patients dying within five years of diagnosis. About half of those affected have a type called heart failure with reduced ejection fraction (HFrEF), in which the heart's left ventricle can't contract effectively.

Why adherence remains low

Current guidelines for treating HFrEF recommend the simultaneous use of four types of medications: beta blockers, renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists. Although studies have shown this combination can cut in half the number of deaths in HFrEF patients compared with a previously recommended two-drug regimen, adherence to this quadruple therapy is low. Only 15% of patients hospitalized with HFrEF receive it, and taking these drugs in optimal doses is even rarer, Pandey explained.

To help improve adherence to the guideline-recommended multidrug therapy, Pandey and his colleagues tested combining these medications into a single daily pill—a strategy that has shown success in treating atherosclerotic cardiovascular disease, a condition in which plaque builds up in the arteries and requires a similarly complicated drug dosing regimen. The team enrolled 212 heart failure patients at Parkland Memorial Hospital and William P. Clements Jr. University Hospital. Both are teaching hospitals for UT Southwestern; Parkland is a safety-net county hospital.

Patients from both sites had similar characteristics, with a median age of 54 years, 78% male, 54% Black, and 33% Hispanic. About 68% were uninsured or relied on health care programs for indigent patients—known barriers to achieving optimal therapy.

How the trial was structured

The researchers randomized these patients into two groups. One took the beta blockers, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists combined into a polypill once daily; the renin-angiotensin system inhibitors were taken separately. The polypill was available in several different formulations, allowing doctors to vary the dose of individual components as needed. The other group took each drug separately.

The team followed the patients for six months. The primary outcome of the study was change in heart function, or left ventricular ejection fraction, assessed by cardiac MRI. The investigators also tracked adherence to the prescribing regimens through blood tests of drug concentrations in the serum, side effects, hospitalizations, and deaths.

Stronger heart function and follow-through

Results showed a significantly greater improvement in heart function of 3.3 percentage points in left ventricular ejection fraction among participants in the polypill group compared with those who took the pills separately. There was also a marked gain in medication adherence: 79% of patients in the polypill group had detectable blood levels of all tested medications, confirming they were taking their drugs, compared with 54% of those taking the drugs separately. By six months, nearly all polypill patients (97%) were receiving all four recommended drug classes, versus 78% in the comparison group.

There were also large gains in reducing the risk of heart failure, hospitalizations or emergency visits. Those taking the polypill had a 60% lower rate of heart failure, hospitalizations or emergency department visits and fewer serious side effects than those taking the drugs individually.

A model for complex regimens

Together, Pandey said, these findings suggest that a polypill holds significant promise for treating HFrEF and might improve outcomes for other conditions that require treatment with multiple daily drugs.

"For decades we've had medications that meaningfully extend and improve the lives of heart failure patients, yet most people never receive them at the right doses," said senior author Thomas J. Wang, M.D., dean of the University of Michigan Medical School and Josiah Macy Jr. Professor, who formerly served as chair of internal medicine at UT Southwestern. "POLY-HF shows that simplifying how these drugs are delivered can close that gap, and the principle could extend to many other conditions that depend on complex daily regimens."

Publication details

Ambarish Pandey et al, Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial, Nature Medicine (2026). DOI: 10.1038/s41591-026-04504-5

Journal information: Nature Medicine

Key medical concepts

Heart FailureLeft Ventricular Ejection Fraction

Clinical categories

CardiologyCommon illnesses & Prevention Provided by UT Southwestern Medical Center Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: 'Polypill' for heart failure cuts hospitalizations and ER visits by 60% in trial (2026, July 2) retrieved 2 July 2026 from https://medicalxpress.com/news/2026-07-polypill-heart-failure-hospitalizations-er.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.